Expression of cyclin D1 and Ki-67 in squamous cell carcinoma of the oral cavity: clinicopathological and prognostic significance. 2002

Juan Carlos de Vicente, and Agustín Herrero-Zapatero, and Manuel Florentino Fresno, and Juan Sebastián López-Arranz
Department of Oral and Maxillofacial Surgery, University Hospital of Oviedo, Oviedo, Spain. jvicente@correo.uniovi.es

The prognostic and clinicopathologic significance of cyclin D1 and Ki-67 expressions was studied in oral squamous cell carcinomas. We performed an immunohistochemical study to determine the level of expression of cyclin D1 and Ki-67 labelling index in tumor specimens obtained from 35 patients, of whom 14 died as a result of recurrent disease, and 20 were free of recurrence at the end of the follow-up period. Overexpression of cyclin D1 was significantly associated with regional lymph node metastases (P=0.00005) and advanced tumor stage (P=0.0007). The relative risk for nodal metastases in the cases that overexpressed cyclin D1 was 2.6. The Ki-67 labelling index was significantly (P=0.001) higher in tumors with poor histologic grade of differentiation. Our results showed that cyclin D1 is a useful prognostic factor, and suggested it could be a marker to help determine the appropriate treatment for patients with oral squamous cell carcinoma. Cyclin D1 and Ki-67 overexpression were positively correlated.

UI MeSH Term Description Entries
D007150 Immunohistochemistry Histochemical localization of immunoreactive substances using labeled antibodies as reagents. Immunocytochemistry,Immunogold Techniques,Immunogold-Silver Techniques,Immunohistocytochemistry,Immunolabeling Techniques,Immunogold Technics,Immunogold-Silver Technics,Immunolabeling Technics,Immunogold Silver Technics,Immunogold Silver Techniques,Immunogold Technic,Immunogold Technique,Immunogold-Silver Technic,Immunogold-Silver Technique,Immunolabeling Technic,Immunolabeling Technique,Technic, Immunogold,Technic, Immunogold-Silver,Technic, Immunolabeling,Technics, Immunogold,Technics, Immunogold-Silver,Technics, Immunolabeling,Technique, Immunogold,Technique, Immunogold-Silver,Technique, Immunolabeling,Techniques, Immunogold,Techniques, Immunogold-Silver,Techniques, Immunolabeling
D008207 Lymphatic Metastasis Transfer of a neoplasm from its primary site to lymph nodes or to distant parts of the body by way of the lymphatic system. Lymph Node Metastasis,Lymph Node Metastases,Lymphatic Metastases,Metastasis, Lymph Node
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009062 Mouth Neoplasms Tumors or cancer of the MOUTH. Cancer of Mouth,Mouth Cancer,Oral Cancer,Oral Neoplasms,Cancer of the Mouth,Neoplasms, Mouth,Neoplasms, Oral,Cancer, Mouth,Cancer, Oral,Cancers, Mouth,Cancers, Oral,Mouth Cancers,Mouth Neoplasm,Neoplasm, Mouth,Neoplasm, Oral,Oral Cancers,Oral Neoplasm
D009363 Neoplasm Proteins Proteins whose abnormal expression (gain or loss) are associated with the development, growth, or progression of NEOPLASMS. Some neoplasm proteins are tumor antigens (ANTIGENS, NEOPLASM), i.e. they induce an immune reaction to their tumor. Many neoplasm proteins have been characterized and are used as tumor markers (BIOMARKERS, TUMOR) when they are detectable in cells and body fluids as monitors for the presence or growth of tumors. Abnormal expression of ONCOGENE PROTEINS is involved in neoplastic transformation, whereas the loss of expression of TUMOR SUPPRESSOR PROTEINS is involved with the loss of growth control and progression of the neoplasm. Proteins, Neoplasm
D009367 Neoplasm Staging Methods which attempt to express in replicable terms the extent of the neoplasm in the patient. Cancer Staging,Staging, Neoplasm,Tumor Staging,TNM Classification,TNM Staging,TNM Staging System,Classification, TNM,Classifications, TNM,Staging System, TNM,Staging Systems, TNM,Staging, Cancer,Staging, TNM,Staging, Tumor,System, TNM Staging,Systems, TNM Staging,TNM Classifications,TNM Staging Systems
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D002294 Carcinoma, Squamous Cell A carcinoma derived from stratified SQUAMOUS EPITHELIAL CELLS. It may also occur in sites where glandular or columnar epithelium is normally present. (From Stedman, 25th ed) Carcinoma, Epidermoid,Carcinoma, Planocellular,Carcinoma, Squamous,Squamous Cell Carcinoma,Carcinomas, Epidermoid,Carcinomas, Planocellular,Carcinomas, Squamous,Carcinomas, Squamous Cell,Epidermoid Carcinoma,Epidermoid Carcinomas,Planocellular Carcinoma,Planocellular Carcinomas,Squamous Carcinoma,Squamous Carcinomas,Squamous Cell Carcinomas
D005260 Female Females

Related Publications

Juan Carlos de Vicente, and Agustín Herrero-Zapatero, and Manuel Florentino Fresno, and Juan Sebastián López-Arranz
January 2020, Asian Pacific journal of cancer prevention : APJCP,
Juan Carlos de Vicente, and Agustín Herrero-Zapatero, and Manuel Florentino Fresno, and Juan Sebastián López-Arranz
January 2007, Anticancer research,
Juan Carlos de Vicente, and Agustín Herrero-Zapatero, and Manuel Florentino Fresno, and Juan Sebastián López-Arranz
August 2018, Oral oncology,
Juan Carlos de Vicente, and Agustín Herrero-Zapatero, and Manuel Florentino Fresno, and Juan Sebastián López-Arranz
November 2015, Medicina oral, patologia oral y cirugia bucal,
Juan Carlos de Vicente, and Agustín Herrero-Zapatero, and Manuel Florentino Fresno, and Juan Sebastián López-Arranz
January 2018, OncoTargets and therapy,
Juan Carlos de Vicente, and Agustín Herrero-Zapatero, and Manuel Florentino Fresno, and Juan Sebastián López-Arranz
June 2011, Hua xi kou qiang yi xue za zhi = Huaxi kouqiang yixue zazhi = West China journal of stomatology,
Juan Carlos de Vicente, and Agustín Herrero-Zapatero, and Manuel Florentino Fresno, and Juan Sebastián López-Arranz
January 2016, Journal of Cancer,
Juan Carlos de Vicente, and Agustín Herrero-Zapatero, and Manuel Florentino Fresno, and Juan Sebastián López-Arranz
January 2023, Bioinformation,
Juan Carlos de Vicente, and Agustín Herrero-Zapatero, and Manuel Florentino Fresno, and Juan Sebastián López-Arranz
July 2017, Oncology letters,
Juan Carlos de Vicente, and Agustín Herrero-Zapatero, and Manuel Florentino Fresno, and Juan Sebastián López-Arranz
July 2010, Oral oncology,
Copied contents to your clipboard!